Evotec

Evotec is a global biotechnology company that specializes in drug discovery and development. The company was founded in 1993 and is headquartered in Hamburg, Germany. Evotec's primary focus is on the development of small molecule drugs to treat diseases with high unmet medical need.

History

Evotec was founded in 1993 by a group of scientists from the Max Planck Institute for Biochemistry in Martinsried. The company initially focused on providing research services to pharmaceutical and biotechnology companies. Over the years, Evotec has expanded its operations and now offers a broad range of drug discovery solutions, including target identification and validation, lead discovery and optimization, and preclinical and clinical development.

Operations

Evotec operates through two business segments: EVT Execute and EVT Innovate. The EVT Execute segment provides drug discovery services, including target identification, lead optimization, and industrial scale synthesis. The EVT Innovate segment focuses on the development of proprietary drug candidates.

Evotec has a diverse pipeline of drug candidates in various stages of development. These candidates are being developed to treat a range of diseases, including neurodegenerative diseases, cancer, and infectious diseases.

Partnerships

Evotec has established numerous partnerships with pharmaceutical and biotechnology companies, academic institutions, and non-profit organizations. These partnerships have enabled Evotec to access novel drug targets and technologies, and to share the risks and rewards of drug discovery and development.

Future Outlook

Evotec continues to invest in its drug discovery and development capabilities, and to seek out new partnerships and collaborations. The company's goal is to become a leading player in the global biotechnology industry, and to bring innovative new medicines to patients in need.